UCB SA - BNP Paribas Fortis

More documents

Recommendations

Info

Company name Registered office UCB Pharma AS ................................................... Cemil Topuzlu Cad Is Bankasi Bloklari D Blok, Kat 4 Daire 7, Fenerbahce, 81030 Istanbul, Turkey UCB Pharma A.S. ................................................ Brynsveien 96, 1352 Kolsas Baerum, Norway UCB Pharma A.S. (Norway) ................................ Grini Naeringspark, 8b, Osteras 1361, Baerum, Norway UCB Pharma B.V. (Nederland) ............................ Lage Mosten 33, 4822 NK Breda, The Netherlands UCB Pharma Canada Inc ..................................... 4145 North Service Road 200, Burlington, ONL7L 6A3, Canada A11250830/2.25/23 Oct 2009 114 Percentage Voting rights at shareholders’ meeting UCB Pharma GmbH ............................................ Brünnerstrasse 73/5, 1210 Wien, Austria 100 UCB (Pharma) Ireland Ltd. .................................. United Drug House Magna Drive, Magna Business Park, City West Road, Dublin 24, Ireland UCB Pharma LLC (Russia) .................................. 5 Shturvalnaya str. Bldg 1, Moscow 125364, Russia UCB Pharma Ltd. ................................................. 208 Bath Road, Slough, Berkshire, S14 3WE U.K. UCB Pharma OY (Finland) .................................. Melminkaari 5, 00700 Helsinki, Finland 100 UCB Pharma (Produtos Farmaceuticos) Lda ....... Rua Gregorio Lopes, Lote 1597-1°, 1400- 195 Lisboa, Portugal UCB Pharma Romania S.R.L. .............................. 37 Paris Street, Bucharest 11814, Romania 100 UCB Pharma S.A. ................................................ Avenida de Barcelona 239, 08750 Molins de Rei Barcelona, Spain UCB Pharma SA (Belgium) ................................. Route de Lennik 437, 1070 Brussels, Belgium UCB Pharma S.A. (France) .................................. 21 Rue de Neuilly, 92003 Nanterre, France 100 UCB Pharma SpA ................................................ Via Praglia 15, 10044 Pianezzo TO, Italy 100 UCB Pharma Sp.zo.o. (Poland) ............................ Ul. Przyokopowa 43, 01-208 Warszawa, Poland 100 100 100 100 100 100 100 100 100 100 100 100
Company name Registered office UCB Pharma S.R.O. (Czech Republic) ................ Budova Raiffeisen Stavebni Sporitelny, Konenvova 99, 13000 Praha, Czech Republic UCB Research Inc. ............................................... 1950 Lake Park Drive, 30080 Atlanta Georgia, U.S.A. UCB S.C.A. .......................................................... Rue Eugène Rupert, 12, Luxembourg, 2453, Luxembourg UCB Services Ltd. ............................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. UCB SP GmbH .................................................... Alfred Nobel Strasse, 10, Monheim am Rhein, 40789, Germany UCB T&R Graham Ltd. ....................................... c/o HLB Breckenridge House 274 Sauchiehall Street, Glasgow, G2 3EH U.K. UCB Technologies Inc ......................................... C T Corporation System 111 Eight Ave, New York, 10011 New York, USA UCB Trading (Shanghai) Co. Ltd. ........................ Suite 2802 Raffles City Shanghai Office Tower, 268 Tibet Road Central, Shanghai, 200001, China UCB Watford Ltd. ................................................ 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Uni Mediflex Private Ltd. .................................... G-6 Venus Apartments RG Thandani Marg Worli, 400018 Mumbai, India Upstate Pharma LLC ............................................ 755 Jefferson Road, 14623 Rochester New York, U.S.A. Vedim Pharma GmbH .......................................... Hüttenstrasse 205 PF 1340, 50170 Kerpen- Sindorf, Germany Vedim Sp.zo.o. ..................................................... Ul. Przyokopowa 43, 01-208 Warszawa, Poland Vedim Pharma S.A. .............................................. Avenida de Barcelona 239, 08750 Molins de Rei Barcelona, Spain Vedim S.A. de CV ................................................ Homero#440 7fl Col. Chapultepec Morales, 11570 Mexico D.F., Mexico Vedim Pharma (Prod. Quimicos e Farma) Lda .... Rua Carlos Calisto 4B, 1400-043 Lisboa, Portugal A11250830/2.25/23 Oct 2009 115 Percentage Voting rights at shareholders’ meeting 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Page 1 and 2:
A11250830/2.25/23 Oct 2009 UCB SA (
Page 3 and 4:
A11250830/2.25/23 Oct 2009 3 RESPON
Page 5 and 6:
A11250830/2.25/23 Oct 2009 5 WARNIN
Page 7 and 8:
A11250830/2.25/23 Oct 2009 7 PART I
Page 9 and 10:
Specified Denomination per Bond Min
Page 11 and 12:
Trading on the regulated market of
Page 13 and 14:
- Reliance on the procedures of the
Page 15 and 16:
and federal governmental entities,
Page 17 and 18:
If any of the UCB Group’s major p
Page 19 and 20:
The UCB Group relies upon third-par
Page 21 and 22:
other U.S. federal and state govern
Page 23 and 24:
either to remediate certain sites o
Page 25 and 26:
(iii) have sufficient financial res
Page 27 and 28:
(i) EU Savings Directive Under the
Page 29 and 30:
(o) The Domiciliary Agent is not re
Page 31 and 32:
PART III: DOCUMENTS INCORPORATED BY
Page 33 and 34:
• Press release of 26 June 2009:
Page 35 and 36:
The Bonds constitute direct, uncond
Page 37 and 38:
“Interest Payment Date” has the
Page 39 and 40:
When interest is required to be cal
Page 41 and 42:
"Calculation Agent" means Fortis Ba
Page 43 and 44:
The Issuer reserves the right under
Page 45 and 46:
any step is taken to enforce it (in
Page 47 and 48:
12 Notices Notices to the Bondholde
Page 49 and 50:
1. SUMMARY PART VI: DESCRIPTION OF
Page 51 and 52:
Marketing & selling expenses Resear
Page 53 and 54:
In 2008, the Issuer announced sever
Page 55 and 56:
Issuer is developing from its stron
Page 57 and 58:
Parkinson’s disease. Following a
Page 59 and 60:
Keppra® is one of the core product
Page 61 and 62:
that remission is possible with no
Page 63 and 64: (d) Manufacturing and supply of raw
Page 65 and 66: NET SALES FOR MAIN PRODUCTS BY REGI
Page 67 and 68: (a) a strategic focus on severe CNS
Page 69 and 70: ongoing and results are expected du
Page 71 and 72: Cimzia® (certolizumab pegol) Cimzi
Page 73 and 74: • Pfizer Inc.: The UCB Group is p
Page 75 and 76: esearch, regulatory, manufacturing,
Page 77 and 78: Neupro® (rotigotine; patch) Februa
Page 79 and 80: Before a drug can qualify for marke
Page 81 and 82: control mechanisms operate differen
Page 83 and 84: year term following a specific regu
Page 85 and 86: pain; which expires with the last t
Page 87 and 88: Group. The UCB Group treats any cla
Page 89 and 90: (g) Distilbène Litigation As of th
Page 91 and 92: (n) Competition enquiry in France T
Page 93 and 94: 3 These Directors are representativ
Page 95 and 96: Norman J-Ornstein was appointed to
Page 97 and 98: Mark McDade joined the Issuer as ex
Page 99 and 100: esults or information which is liab
Page 101 and 102: Peter Fellner......................
Page 103 and 104: • the closing price of the Ordina
Page 105 and 106: A11250830/2.25/23 Oct 2009 105 PART
Page 107 and 108: A11250830/2.25/23 Oct 2009 107 PART
Page 109 and 110: Company name Registered office Cist
Page 111 and 112: Company name Registered office Schw
Page 113: Company name Registered office UCB
Page 117 and 118: PART XI: DESCRIPTION OF THE SHARES
Page 119 and 120: According to article 32 of the Arti
Page 121 and 122: Under UCB’s Articles, the Issuer
Page 123 and 124: The Board can also determine when s
Page 125 and 126: 1. BELGIAN TAXATION PART XIII: TAXA
Page 127 and 128: (b) Belgian tax on income and capit
Page 129 and 130: more detailed proposal for amendmen
Page 131 and 132: PART XIV: SUBSCRIPTION AND SALE For
Page 133 and 134: On the date that the subscriptions
Page 135 and 136: 12. DISTRIBUTION OF THE PROSPECTUS
Page 137 and 138: PART XV: GENERAL INFORMATION 1. App
Page 139 and 140: A11250830/2.25/23 Oct 2009 139 Subs
Page 141 and 142: Addressee UCB SA (the « Issuer »)
show all

UCB SA - BNP Paribas Fortis

Create successful ePaper yourself

Delete template?

Save as template?